STOCK TITAN
  1. Home
  2. News
  3. CDXC

ChromaDex Corporation - CDXC STOCK NEWS

Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.

ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.

ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).

The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.

ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.

The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.

Recent Achievements and Current Projects:

  • Continued research and development into NAD+ and its related compounds.
  • Expansion of Tru Niagen® into new markets globally.
  • Ongoing partnerships with leading universities and research institutions.
  • Innovative new product launches aimed at further promoting healthy aging.
News

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the major grocery debut of Tru Niagen® at Sprouts Farmers Market, expanding its reach to health-conscious consumers in over 400 locations across 23 states. Tru Niagen®, the top NAD+ supplement for healthy aging in the US, is now available at Sprouts, showcasing ChromaDex's commitment to enhancing access to its products. The partnership with Sprouts aligns with ChromaDex's goal of transforming the aging process for a broader audience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.25%
Tags
none
-
News

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

Rhea-AI Summary
ChromaDex Corp. announces that its Tru Niagen product line is now third-party verified through the Alkemist Assured program, ensuring quality and transparency in the dietary supplement industry. The company's commitment to excellence and consumer trust is reinforced by this partnership, setting a new industry standard for product verification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
News

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) reported strong financial results for the fourth quarter and full year 2023, with net sales of $21.2 million and $83.6 million, respectively. The company achieved positive net income, gross margin improvements, and positive adjusted EBITDA. Key highlights include the launch of Tru Niagen® Pro 1,000 mg and successful clinical trials showcasing the benefits of Niagen® in various health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
earnings
News

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

Rhea-AI Summary
ChromaDex Corp. (CDXC) schedules a conference call to discuss fourth-quarter 2023 financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences earnings
-
News

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on Monday, February 12, 2024, at 11:00 AM PST. The event will feature the latest investor presentation by CEO Rob Fried and CFO Brianna Gerber, followed by a live Q&A. Registration is limited, but the replay will be available on ChromaDex’s website. For more information, visit www.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
News

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) CEO and CFO will be participating in the Lytham Partners 2024 Investor Select Conference for virtual one-on-one meetings. The event is scheduled for Thursday, February 1, 2024. For more information, visit www.chromadex.com and www.investors.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences
News

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the launch of Tru Niagen, its patented nicotinamide riboside (NR) supplement, to support the US Military Special Operations Forces. The initiative includes an exclusive program that offers Tru Niagen products to active and veteran Military Service Members, reflecting ChromaDex's commitment to the health and well-being of those who serve the Nation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
News

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Rhea-AI Summary
Neurohacker Collective has launched Qualia NAD+ featuring ChromaDex's patented Nicotinamide Riboside (NR) as an NAD+ supplement to boost NAD+ levels in aging Americans. The pilot study resulted in 95% of participants rating the experience as 'excellent' to 'good.' Qualia NAD+ is positioned to become a category leader in NAD+ supplementation, leveraging Niagen, the FDA-notified form of NR, backed by two Nobel Prize winners and over 25 human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
partnership
-
News

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) shares results from a new study on the safety and benefits of high-dose nicotinamide riboside (NR) supplementation for individuals with Parkinson’s disease. The study demonstrated that supplementing individuals with PD with high-dose Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, and was associated with a significant clinical improvement. This marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
clinical trial
News

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the results of a phase II clinical study on Niagen NR, demonstrating up to fourfold increase in NAD+ levels, improved coordination and eye movement in Ataxia Telangiectasia (AT) patients. The study is the longest Niagen NR clinical trial to date, spanning two years, and showcases that long-term Niagen NR is safe and well tolerated. The promising results highlight the potential of Niagen NR in supporting brain health and cognition, indicating a potential therapeutic strategy for AT patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
clinical trial

FAQ

What is the current stock price of ChromaDex Corporation (CDXC)?

The current stock price of ChromaDex Corporation (CDXC) is $7.44 as of November 22, 2024.

What is the market cap of ChromaDex Corporation (CDXC)?

The market cap of ChromaDex Corporation (CDXC) is approximately 559.1M.

What is ChromaDex Corporation's main focus?

ChromaDex focuses on improving healthy aging through scientific research and the development of NAD+ related supplements.

What is Tru Niagen®?

Tru Niagen® is a dietary supplement formulated with Niagen® (nicotinamide riboside), which helps boost NAD+ levels to support healthy aging.

How does ChromaDex generate most of its revenue?

The majority of ChromaDex's revenue comes from its Consumer Products segment, particularly the sales of Tru Niagen®.

On which stock exchange is ChromaDex traded?

ChromaDex is publicly traded on NASDAQ under the symbol CDXC.

What are some of ChromaDex's other products?

In addition to Tru Niagen®, ChromaDex offers PteroPure® (pterostilbene), PureEnergy® (caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).

Who are ChromaDex's research partners?

ChromaDex collaborates with leading universities and research institutions worldwide to advance their scientific research.

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for metabolic processes, which declines with age.

Where can I find more information about ChromaDex?

More information about ChromaDex can be found on their website at www.chromadex.com.

Does ChromaDex offer services apart from consumer products?

Yes, ChromaDex also operates in the Ingredients segment and the Analytical Reference Standards and Services segment.

How is ChromaDex contributing to healthy aging research?

ChromaDex contributes to healthy aging research through its extensive studies on NAD+ and partnerships with global research institutions.

Stock CDXC logo
ChromaDex Corporation

Nasdaq:CDXC

CDXC Rankings

#3033 Ranked by Market Cap
N/A Ranked by Dividends

CDXC Stock Data

559.14M
49.35M
35.39%
23.87%
3.41%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States of America
LOS ANGELES